Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

108.40EUR
13 Jul 2018
Change (% chg)

€0.10 (+0.09%)
Prev Close
€108.30
Open
€107.90
Day's High
€108.50
Day's Low
€106.90
Volume
65,395
Avg. Vol
113,872
52-wk High
€109.90
52-wk Low
€55.05

Latest Key Developments (Source: Significant Developments)

Annual General Meeting Of Morphosys AG Elects New Supervisory Board Members
Friday, 18 May 2018 

May 17 (Reuters) - MorphoSys AG ::DGAP-NEWS: ANNUAL GENERAL MEETING OF MORPHOSYS AG ELECTS NEW SUPERVISORY BOARD MEMBERS.SHAREHOLDERS APPROVED ALL RESOLUTIONS PROPOSED BY COMPANY'S MANAGEMENT AT ITS ANNUAL GENERAL MEETING ON THURSDAY.PROPOSAL APPROVED INCLUDE APPOINTMENT OF PRICEWATERHOUSECOOPERS AG AS AUDITOR FOR 2018 FINANCIAL YEAR.  Full Article

Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million
Tuesday, 24 Apr 2018 

April 23 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION.SAYS EXPECTS GROSS PROCEEDS OF TRANSACTION TO AMOUNT TO USD 239,006,800.  Full Article

Morphosys ADS Debut At $26.16, Slightly Above IPO Price
Thursday, 19 Apr 2018 

April 19 (Reuters) - MorphoSys AG ::MORPHOSYS AG ADS DEBUT AT $26.16 ON THE NASDAQ VERSUS IPO PRICE OF $25.04/ADS.  Full Article

Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
Thursday, 19 Apr 2018 

April 18 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ.OFFERING PRODUCED GROSS PROCEEDS OF $207.8 MILLION FROM SALE OF 2.07 MILLION NEW ORDINARY SHARES IN FORM OF 8.3 MILLION ADS AT $25.04 PER ADS.  Full Article

Morphosys to increase capital to implement Offering Of 8.3 mln ADS
Wednesday, 18 Apr 2018 

April 17 (Reuters) - MorphoSys AG ::DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES.TO INCREASE SHARE CAPITAL OF MORPHOSYS AG BY ISSUING 2.1 MILLION NEW SHARES, EXCLUDING PRE-EMPTIVE RIGHTS OF EXISTING SHAREHOLDERS.TO IMPLEMENT IPO IN UNITED STATES OF 8.3 MILLION AMERICAN DEPOSITARY SHARES PURSUANT TO A REGISTRATION STATEMENT ON FORM F-1.PRICING OF OFFERING IS EXPECTED TO OCCUR ON APRIL 18, 2018, FOLLOWING END OF BOOKBUILDING IN UNITED STATES.  Full Article

Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MORPHOSYS AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA.MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA.  Full Article

Morphosys Increases Financial Guidance For 2017
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - MORPHOSYS AG ::INCREASES FINANCIAL GUIDANCE FOR 2017 FOLLOWING SIGNATURE OF REGIONAL LICENSE AGREEMENT FOR ANTIBODY MOR202 WITH I-MAB.‍FOR YEAR 2017, MORPHOSYS NOW EXPECTS REVENUES IN RANGE FROM EUR 63 TO 66 MILLION​.NOW EXPECTS FY EBIT OF EUR -66 TO -71 MILLION (UP FROM PREVIOUSLY EUR -75 TO -85 MILLION).FY ‍PROPRIETARY RESEARCH AND DEVELOPMENT EXPENSES WILL BE IN RANGE FROM EUR 96 TO 100 MILLION (PREVIOUSLY EUR 85 TO 95 MILLION)​.RECEIVES AN IMMEDIATE UPFRONT PAYMENT OF USD 20 MILLION FROM LICENSE AGREEMENT SIGNED.WILL BE ENTITLED TO RECEIVE ADDITIONAL MILESTONE PAYMENTS FROM I-MAB OF UP TO C. USD 100 MILLION.TO BE ENTITLED TO RECEIVE TIERED, DOUBLE-DIGIT ROYALTIES ON NET SALES OF MOR202 IN TERRITORY.SHARES JUMP 5.2 PERCENT​.  Full Article

Janssen receives approval for Tremfya in Europe - Morphosys
Thursday, 23 Nov 2017 

Nov 23 (Reuters) - Morphosys AG :Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis.Says is ‍entitled to royalties on net sales of Janssen's Tremfya​.  Full Article

Morphosys Q3 revenue up 20 pct at 15 mln eur​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Morphosys AG :Q3 net loss -24 million eur versus -12.8 million eur loss year ago.Q3 revenue rose 20 percent to 15 million eur.Says ‍group revenue for q3 2017 up 20% to eur 15.0 million (q3 2016: eur 12.5 million)​.Says Dr. Markus Enzelberger, interim CSO, now appointed CSO​.Says ‍company confirms financial guidance​.Says ‍earnings before interest and taxes (ebit) in q3 2017 amounted to eur -23.5 million (q3 2016: eur -13.1 million)​.  Full Article

Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Morphosys AG -:DGAP-Adhoc: Adhoc: Morphosys receives FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL.Morphosys AG says ‍receives FDA breakthrough therapy designation for its antibody MOR208 in relapsed/refractory DLBCL​.  Full Article

German stocks - Factors to watch on July 11

BERLIN/FRANKFURT, July 11 The following are some of the factors that may move German stocks on Wednesday: